Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 6/20 | 0.43 |
| ▸ | PLAT | P00750 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16048043 | 0.90 | KDM5A (0.50) | KDM5APLATPDE3BPDE3AKDM4D | |
| SCHEMBL16047079 | 0.86 | KDM5A (0.41) | KDM5APLATPDE3BPDE3AKDM4D | |
| SCHEMBL16046669 | 0.84 | KDM5A (0.48) | KDM5APLATPDE3BPDE3AKDM4D | |
| SCHEMBL17547884 | 0.82 | KDM5A (0.40) | KDM5APLATKDM4DKDM4EALDH1A1 | |
| SCHEMBL16047853 | 0.82 | KDM5A (0.37) | KDM5APLATKDM4DKDM4EHSD17B10 | |
| SCHEMBL16046861 | 0.81 | KDM5A (0.46) | KDM5APLATPDE3BPDE3AKDM4D | |
| SCHEMBL18159119 | 0.81 | KDM5A (0.53) | KDM5APLATPDE3BPDE3AKDM4D | |
| SCHEMBL16047337 | 0.78 | KDM4E (0.47) | KDM5APLATKDM4EALDH1A1HSD17B10 | |
| SCHEMBL16047129 | 0.78 | KDM5A (0.50) | KDM5APLATPDE3BPDE3AKDM4D | |
| SCHEMBL9204181 | 0.78 | KDM4E (0.45) | KDM5APLATKDM4DKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2020219963-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | KDM5A 1/4885PLAT 4107/4885PDE3B 608/4885 |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM1B, DOT1L, EHMT1 | KDM5A 4/4885PLAT 3741/4885PDE3B 279/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | KDM5A 1/4885PLAT 4107/4885PDE3B 608/4885 |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MUC1, FABP6 | KDM5A 4362/4885PLAT 270/4885PDE3B 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.